{"url_path":"/sec/nmtc/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1500198/0001213900-26-054749-index.html","accession_number":"0001213900-26-054749","cik":"0001500198","ticker":"NMTC","issuer_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1500198/0001213900-26-054749-index.html","primary_entity_key":"0001500198","primary_entity_name":"NEUROONE MEDICAL TECHNOLOGIES Corp"},"word_count":77,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n \n\nRule 10b5-1 Trading\nPlans – Directors and Section 16 Officers\n\n \n\nDuring the three months\nended March 31, 2026, none of the Company’s directors or Section 16 officers adopted or terminated any contract,\ninstruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions\nof Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement”.\n\n** **\n\n38\n\n \n\n** **\n\n**NeuroOne Medical Technologies Corporation**\n\n**Form 10-Q**"}